Modernizing Opioid Treatment Access Act 2.0 of 2026
- Bill Number
- S. 4941
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Status
- Introduced
- Latest Action
- 2026-06-24: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-07-07T04:53:30Z
AI-Generated Summary
Modernizing Opioid Treatment Access Act 2.0 of 2026 (S. 4941)
Purpose
This legislation aims to increase access to methadone for treating opioid use disorder by allowing certain qualified practitioners to prescribe it for dispensing at pharmacies, in addition to existing opioid treatment programs.
Key Provisions
- Amends Section 303(h) of the Controlled Substances Act to waive standard requirements for methadone when prescribed by registered practitioners.
- Permits the Attorney General, in consultation with the Secretary of Health and Human Services, to register addiction medicine physicians or addiction psychiatrists (with specific board certifications) or other qualified practitioners to prescribe methadone.
- Requires prescriptions to be issued electronically, limited to liquid or dispersible tablet forms, and compliant with federal and state quantity limits.
- Mandates informed consent from patients, including details on confidentiality differences between pharmacy dispensing and traditional programs.
- Allows treatment via telemedicine and states that pharmacies need no separate registration to dispense such prescriptions.
- Enables states to request that the Attorney General stop new registrations, revoke existing ones, or deny applications within their borders.
- Requires the Drug Enforcement Administration to submit annual reports to Congress on registrations, state opt-outs, violations, and pharmacy orders.
Significant Changes to Existing Law
- Shifts from the prior model where methadone for opioid use disorder was primarily available only through certified opioid treatment programs, by creating a parallel pathway for pharmacy-based dispensing under practitioner oversight.
- Introduces new registration and qualification standards separate from general controlled substance rules.
Potential Impacts
- Government agencies: Increases administrative workload for the Drug Enforcement Administration in processing registrations and reports, and involves the Department of Health and Human Services in setting qualification standards.
- Citizens: May improve treatment availability for individuals with opioid use disorder, particularly in areas with limited program access, while maintaining requirements for ongoing care through treatment programs.
- No direct effects on international relations are outlined.
Main Stakeholders Affected
- Patients seeking treatment for opioid use disorder
- Qualified physicians (addiction medicine specialists and psychiatrists)
- Pharmacies and opioid treatment programs
- State governments (with opt-out authority)
- Federal agencies including the Drug Enforcement Administration and Department of Health and Human Services
Notable Legal, Constitutional, or Political Implications
- Modifies federal controlled substances regulations to balance expanded access with safeguards such as electronic prescribing and state flexibility.
- Includes reporting and revocation mechanisms to address compliance and potential misuse.
- Sponsored on a bipartisan basis, reflecting a focus on public health policy adjustments without altering core constitutional divisions of power over drug regulation.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Sen. Paul, Rand [R-KY], Sen. Warren, Elizabeth [D-MA], Sen. Hassan, Margaret Wood [D-NH], Sen. Duckworth, Tammy [D-IL], Sen. Booker, Cory A. [D-NJ]
Recent Actions
- 2026-06-24: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-06-24: Introduced in Senate
Bill Versions
- Modernizing Opioid Treatment Access Act 2.0 of 2026 — issued 2026-06-24 — PDF (6 pages)